Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.
The drug is still associated with a lower liver cancer rate than Baraclude.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
People who took Viread were about two thirds less likely to develop HCC, but this could be related to other factors as well.
People who added ABI-H0731 saw greater viral load reductions than those who used nucleoside/nucleotide analogues alone.
The FDA’s revision was based on two randomized trials of Viread (tenofovir disoproxil fumarate) use in 2- through 11-year-olds.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Taking Vemlidy rather than Viread as prophylaxis against hepatitis B is tied to better markers of kidney and bone health.
Among those who switched their hep B treatment, Vemlidy may also be tied to a higher chance of ALT liver enzyme normalization.
Researchers analyzed a cohort of South Koreans taking Viread (tenofovir disoproxil fumarate) or Baraclude (entecavir) for hepatitis B.
Nevertheless, researchers advise careful kidney monitoring when pairing the medications.
Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.
A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.